notice of annual general meeting.

Some info from it - highlights what development agreement might be worth. In AS's pay packages. Page 47 of Notice.

The principal terms of the 1,166,000 shares of restricted stock to be granted to Mr. Shortall are as follows:
(a) Grant Date: Subject to stockholder approval being obtained for Proposals No. 11 and 12, the
restricted stock will be granted to Mr. Shortall as soon as practicable after the meeting. Because there are not
sufficient shares remaining under the Stock Plan at this time to fulfill the proposed grant of restricted stock and
Options, the grant date is anticipated to be January 3, 2012, after the annual adjustment to the Stock Plan share
reserve is effectuated, as further described under Proposal No. 12 on page 44, provided that Proposal No. 12 is
approved by stockholders.
(b) Grant Price: There is no consideration payable for the grant of the restricted stock.
(c) Exercise Price: There is no consideration payable on the vesting of the restricted stock.
(d) Vesting Conditions: The shares of restricted stock are scheduled to vest as follows:
• Product shipment to a pharmaceutical company for drug stability studies or drug clinical trials — 5% per
drug.
• The signing of a development agreement with a pharmaceutical company for the development or customization
of a Unilife product with scheduled payments of up to $3,000,000—5% per agreement.
• The signing of a development agreement with a pharmaceutical company for the development or customization
of a Unilife product with scheduled payments between $3,000,000 and $5,000,000—10% per
agreement.
• The signing of a development agreement with a pharmaceutical company for the development or customization
of a Unilife product with scheduled payments in excess of $5,000,000—20% per agreement.
• The signing of a commercial supply agreement for a Unilife product with sales of up to $25,000,000—15%
per agreement.
42
• The signing of a commercial supply agreement for a Unilife product with sales in excess of $25,000,000—
25% per agreement.
• Annual revenue in excess of $100,000,000 —50%.
• Annual revenue in excess of $200,000,000 —100%.